Promising Anti-HIV Compounds in Preclinical or Early Clinical Development

Abstract

In the past several years the focus of drug discovery and development for HIV infection has shifted from nucleoside inhibitors of reverse transcriptase (RT) to non-nucleoside RT inhibitors (NNRTI) and most recently to protease inhibitors, all of which already have been discussed at this meeting. Among the other virus-specific targets for therapeutic intervention, several are recognized as having potential for clinical success and thus are the focus of extensive preclinical and/or clinical investigations. The compounds to be discussed here were selected because of similarities in viral target or because of ongoing clinical interest as indicated by clinical trials in progress. Selection for discussion in this paper does not imply endorsement or support by the Division of AIDS, NIAID.